Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances

Key Points

• Compass Pathways expects to complete its FDA application for COMP360 in the fourth quarter of 2026, targeting a potential U.S. launch in the first half of 2027. The company has begun a rolling submission, supported by Breakthrough Therapy designation and a priority review voucher.
• Commercial preparations are underway, including collaborations with more than 1,000 Spravato treatment sites and plans to focus on provider training, reimbursement support and patient materials. However, launch timing remains subject to FDA review and potential DEA and state-level rescheduling because COMP360 is a Schedule I product.
• Compass reported that COMP360 produced rapid, durable benefits in Phase III treatment-resistant depression trials, with effects lasting at least six months after limited treatments. The company is also advancing a late-stage study of COMP360 for PTSD, a market it estimates includes about 13 million U.S. adults.

Compass Pathways NASDAQ: CMPS said it remains on track to complete a new drug application for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter of this year, with a potential U.S. launch expected in the first half of 2027.

During Canaccord Genuity’s Growth Conference, Chief Commercial Officer Lori Englebert said the company has begun submitting portions of its application under a rolling submission process and that the Food and Drug Administration is actively reviewing early materials. Compass received a national priority review voucher in April and has Breakthrough Therapy designation for the program, she said.

Englebert said the timing of an FDA decision remains uncertain, including whether the agency will use a traditional 60-day filing acceptance period. She said Compass expects a priority-review timetable but noted that the FDA has set a one- to two-month review target associated with the voucher, which is a target rather than a guaranteed deadline.

COMP360 is a Schedule I product, meaning that a potential approval would also need to be followed by Drug Enforcement Administration rescheduling and subsequent state-level scheduling actions. Englebert said the DEA has traditionally had 90 days after FDA approval to complete rescheduling, although an executive order issued in April encouraged greater coordination between the FDA and DEA to expedite the process.

Launch preparation and provider infrastructure

Compass said it expects to be “launch-ready” by the end of this year, while distinguishing that operational readiness from the actual commercial launch date. Englebert said the company believes a first-half 2027 launch timeline is “solid” given the remaining regulatory and scheduling uncertainties.

The company is preparing for a commercial rollout centered on a limited group of providers already equipped to administer multi-hour psychiatric treatments. Englebert said fewer than 10,000 prescribers currently prescribe Johnson & Johnson’s Spravato, and Compass views those providers as a concentrated potential customer base with relevant clinical infrastructure.

“We know exactly who the treaters are, and it is very small,” Englebert said, contrasting the potential COMP360 launch with traditional antidepressant launches that can involve outreach to tens of thousands of physicians.

Chief Patient Officer Steve Levine said Compass has established strategic collaborations encompassing more than 1,000 sites that currently deliver Spravato. The company’s medical science liaison team has also been meeting with providers to understand implementation considerations, he said.

Englebert said Compass plans to focus on reimbursement support, provider education, patient materials and training related to potential risk evaluation and mitigation system requirements. She said the initial commercial ramp could be measured as the company prioritizes positive early experiences for both providers and patients.

Patient experience and treatment profile

Levine, a psychiatrist by training, said COMP360’s clinical profile differs substantially from traditional daily antidepressant treatment. He cited the company’s two positive Phase III trials in treatment-resistant depression and said the program has shown a rapid onset of effect, with a statistically significant and clinically meaningful difference on the Montgomery-Åsberg Depression Rating Scale, or MADRS, observed the day after the first administration.

He also said COMP360 has demonstrated durability lasting at least six months following one, two or potentially three treatments, according to the company’s discussion of its clinical data. Levine described the safety profile as reassuring, with no unexpected adverse events reported and most adverse events characterized as mild to moderate, transient and occurring on the administration day.

COMP360 would involve a roughly six-hour clinic visit, Levine said. During administration, patients typically take a single oral capsule, lie down with an eye shade and listen to music. He cited a post-hoc analysis of audio recordings from Compass’s Phase II post-traumatic stress disorder trial that found sessions were nearly 80% silent.

By comparison, Levine said Spravato generally involves a three-hour appointment and frequent repeat visits, including twice-weekly treatment during the first month and ongoing maintenance treatment that is often weekly. He said the lower anticipated number of COMP360 treatment sessions could make the therapy less disruptive for patients and caregivers despite its longer single-day visit.

Payer discussions and PTSD program

Englebert said Compass is actively discussing COMP360’s potential economic value with payers, particularly its reported rapid effect and durability in a difficult-to-treat patient population. She cautioned that payer interest does not necessarily translate into immediate access or favorable reimbursement terms. The company has not disclosed pricing plans.

Compass is also advancing COMP360 in PTSD. Levine said the company is screening patients for a late-stage Phase IIb/III study intended to serve as a single study for potential approval. He said the prior Phase II PTSD study, published last year, was primarily focused on feasibility and safety but also produced what the company views as encouraging response and remission signals on the CAPS-5 efficacy measure.

Levine said approximately 13 million U.S. adults live with PTSD and that the condition has had no new pharmaceutical approval in more than 25 years. He also pointed to commercial overlap between treatment-resistant depression and PTSD, citing high rates of comorbidity between the conditions.

About Compass Pathways (NASDAQ:CMPS)

Compass Pathways NASDAQ: CMPS is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source